Melanoma treatment with intratumoral electroporation of tavokinogene telseplasmid (pIL-12, tavokinogene telseplasmid)

IFN-γ–related mRNA profile predicts clinical response to PD-1 blockade

(2017) Mark Ayers et al.   JOURNAL OF CLINICAL INVESTIGATION

Nivolumab in metastatic urothelial carcinoma after platinum therapy (CheckMate 275): a multicentre, single-arm, phase 2 trial

(2017) Padmanee Sharma et al.   LANCET ONCOLOGY

Pembrolizumab as Second-Line Therapy for Advanced Urothelial Carcinoma

(2017) Joaquim Bellmunt et al.   NEW ENGLAND JOURNAL OF MEDICINE

Interferon Receptor Signaling Pathways Regulating PD-L1 and PD-L2 Expression

(2017) Angel Garcia-Diaz et al.   Cell Reports

The Safety and Immunogenicity of an Interleukin-12–Enhanced Multiantigen DNA Vaccine Delivered by Electroporation for the Treatment of HIV-1 Infection

(2016) Jeffrey M. Jacobson et al.   JAIDS-JOURNAL OF ACQUIRED IMMUNE DEFICIENCY SYNDROMES

Programmed Death-Ligand 1 Expression and Response to the Anti–Programmed Death 1 Antibody Pembrolizumab in Melanoma

(2016) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Atezolizumab versus docetaxel for patients with previously treated non-small-cell lung cancer (POPLAR): a multicentre, open-label, phase 2 randomised controlled trial

(2016) Louis Fehrenbacher et al.   LANCET

Atezolizumab in patients with locally advanced and metastatic urothelial carcinoma who have progressed following treatment with platinum-based chemotherapy: a single-arm, multicentre, phase 2 trial

(2016) Jonathan E Rosenberg et al.   LANCET

Safety and clinical activity of pembrolizumab for treatment of recurrent or metastatic squamous cell carcinoma of the head and neck (KEYNOTE-012): an open-label, multicentre, phase 1b trial

(2016) Tanguy Y Seiwert et al.   LANCET ONCOLOGY

Nivolumab for Recurrent Squamous-Cell Carcinoma of the Head and Neck

(2016) Robert L. Ferris et al.   NEW ENGLAND JOURNAL OF MEDICINE

Efficacy and safety of electrochemotherapy combined with peritumoral IL-12 gene electrotransfer of canine mast cell tumours

(2016) M. Cemazar et al.   Veterinary and Comparative Oncology

Safe and effective treatment of spontaneous neoplasms with interleukin 12 electro-chemo-gene therapy

(2015) Jeffry Cutrera et al.   JOURNAL OF CELLULAR AND MOLECULAR MEDICINE

Gene Electrotransfer of Canine Interleukin 12 into Canine Melanoma Cell Lines

(2015) Ursa Lampreht et al.   JOURNAL OF MEMBRANE BIOLOGY

Nivolumab in Previously Untreated Melanoma without BRAF Mutation

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab for the Treatment of Non–Small-Cell Lung Cancer

(2015) Edward B. Garon et al.   NEW ENGLAND JOURNAL OF MEDICINE

Nivolumab versus Docetaxel in Advanced Squamous-Cell Non–Small-Cell Lung Cancer

(2015) Julie Brahmer et al.   NEW ENGLAND JOURNAL OF MEDICINE

Pembrolizumab versus Ipilimumab in Advanced Melanoma

(2015) Caroline Robert et al.   NEW ENGLAND JOURNAL OF MEDICINE

A Phase I Double Blind, Placebo-Controlled, Randomized Study of the Safety and Immunogenicity of Electroporated HIV DNA with or without Interleukin 12 in Prime-Boost Combinations with an Ad35 HIV Vaccine in Healthy HIV-Seronegative African Adults

(2015) Juliet Mpendo et al.   PLoS One

Anticancer Cytokines: Biology and Clinical Effects of Interferon-α2, Interleukin (IL)-2, IL-15, IL-21, and IL-12

(2015) Theofanis Floros et al.   SEMINARS IN ONCOLOGY

Interleukin 12: still a promising candidate for tumor immunotherapy?

(2014) Witold Lasek et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

New insights into IL-12-mediated tumor suppression

(2014) S Tugues et al.   CELL DEATH AND DIFFERENTIATION

Insufficient interleukin-12 signalling favours differentiation of human CD4+and CD8+T cells into GATA-3+and GATA-3+ T-bet+subsets in humanized mice

(2014) Eva Billerbeck et al.   IMMUNOLOGY

Cyclophosphamide and IL-12-transduced DCs Enhance the Antitumor Activity of Tumor Antigen–stimulated DCs and Reduce Tregs and MDSCs Number

(2014) Joanna Rossowska et al.   JOURNAL OF IMMUNOTHERAPY

PD-1 blockade induces responses by inhibiting adaptive immune resistance

(2014) Paul C. Tumeh et al.   NATURE

Safety and Comparative Immunogenicity of an HIV-1 DNA Vaccine in Combination with Plasmid Interleukin 12 and Impact of Intramuscular Electroporation for Delivery

(2013) Spyros A. Kalams et al.   JOURNAL OF INFECTIOUS DISEASES

Intratumoral electroporation of IL-12 cDNA eradicates established melanomas by Trp2180–188-specific CD8+ CTLs in a perforin/granzyme-mediated and IFN-γ-dependent manner: application of Trp2180–188 peptides

(2012) Jeong-Im Sin et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Local and systemic antitumor effect of intratumoral and peritumoral IL-12 electrogene therapy on murine sarcoma

(2011) Darja Pavlin et al.   CANCER BIOLOGY & THERAPY

IL-12 inhibits the TGF-β-dependent T cell developmental programs and skews the TGF-β-induced differentiation into a Th1-like direction

(2011) Jana Prochazkova et al.   IMMUNOBIOLOGY

IL-12 triggers a programmatic change in dysfunctional myeloid-derived cells within mouse tumors

(2011) Sid P. Kerkar et al.   JOURNAL OF CLINICAL INVESTIGATION

High response rate after intratumoral treatment with interleukin-2

(2010) Benjamin Weide et al.   CANCER

Intratumoral DNA electroporation induces anti-tumor immunity and tumor regression

(2009) Olga Radkevich-Brown et al.   CANCER IMMUNOLOGY IMMUNOTHERAPY

Phase I Trial of Interleukin-12 Plasmid Electroporation in Patients With Metastatic Melanoma

(2008) Adil I. Daud et al.   JOURNAL OF CLINICAL ONCOLOGY

Adjuvant therapy with pegylated interferon alfa-2b versus observation alone in resected stage III melanoma: final results of EORTC 18991, a randomised phase III trial

(2008) Alexander MM Eggermont et al.   LANCET